These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35361769)

  • 1. Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
    Desnoyers A; Nadler M; Wilson BE; Stajer S; Amir E
    NPJ Breast Cancer; 2022 Mar; 8(1):43. PubMed ID: 35361769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
    Zhang M; Yu X; Wang J; Li Y; Cao L
    J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
    Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent PARP inhibitors for the treatment of patients with
    Poggio F; Bruzzone M; Ceppi M; Conte B; Martel S; Maurer C; Tagliamento M; Viglietti G; Del Mastro L; de Azambuja E; Lambertini M
    ESMO Open; 2018; 3(4):e000361. PubMed ID: 29942664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Jia X; Wang K; Zhuo Q; Zhao Z; Li M
    Clin Breast Cancer; 2024 Jul; 24(5):392-398.e3. PubMed ID: 38580572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
    Chang XF; Ren XL; Yang JQ; Shi JJ; Bai JH; Cui MS; Dong WW
    Breast; 2021 Oct; 59():44-50. PubMed ID: 34130011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
    Mahtani R; Niyazov A; Arondekar B; Lewis K; Rider A; Massey L; Lux MP
    BMC Cancer; 2022 Dec; 22(1):1343. PubMed ID: 36550413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    Valenza C; Trapani D; Gandini S; Sposetti C; Boscolo Bielo L; Marra A; Giarratano T; Favero D; Cortesi L; Moscetti L; Pistelli M; Berardi R; Zambelli A; Lambertini M; Del Mastro L; Guarneri V; Vernieri C; Curigliano G
    Eur J Cancer; 2023 Sep; 190():112944. PubMed ID: 37437366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
    Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
    Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis.
    Sun W; Wu Y; Ma F; Fan J; Qiao Y
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
    Bartoletti M; Pelizzari G; Gerratana L; Bortot L; Lombardi D; Nicoloso M; Scalone S; Giorda G; Baldassarre G; Sorio R; Puglisi F
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    Liu X; Wu K; Zheng D; Luo C; Fan Y; Zhong X; Zheng H
    Front Oncol; 2021; 11():742139. PubMed ID: 34778059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    Xu J; Keenan TE; Overmoyer B; Tung NM; Gelman RS; Habin K; Garber JE; Ellisen LW; Winer EP; Goss PE; Yeap BY; Chabner BA; Isakoff SJ
    Breast Cancer Res Treat; 2021 Oct; 189(3):641-651. PubMed ID: 34417675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.